175 related articles for article (PubMed ID: 33452359)
1. Overexpression of β-Arrestins inhibits proliferation and motility in triple negative breast cancer cells.
Bostanabad SY; Noyan S; Dedeoglu BG; Gurdal H
Sci Rep; 2021 Jan; 11(1):1539. PubMed ID: 33452359
[TBL] [Abstract][Full Text] [Related]
2. β-Arrestin inhibition induces autophagy, apoptosis, G0/G1 cell cycle arrest in agonist-activated V2R receptor in breast cancer cells.
Donia T; Abouda M; Kelany M; Hessien M
Med Oncol; 2021 Mar; 38(4):38. PubMed ID: 33721131
[TBL] [Abstract][Full Text] [Related]
3. FRZB is Regulated by the Transcription Factor EGR1 and Inhibits the Growth and Invasion of Triple-Negative Breast Cancer Cells by Regulating the JAK/STAT3 Pathway.
Liu H; Mei Y; Ma X; Zhang X; Nie W
Clin Breast Cancer; 2022 Oct; 22(7):690-698. PubMed ID: 35787980
[TBL] [Abstract][Full Text] [Related]
4. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
5. Targeting of beta-arrestin2 to the centrosome and primary cilium: role in cell proliferation control.
Molla-Herman A; Boularan C; Ghossoub R; Scott MG; Burtey A; Zarka M; Saunier S; Concordet JP; Marullo S; Benmerah A
PLoS One; 2008; 3(11):e3728. PubMed ID: 19008961
[TBL] [Abstract][Full Text] [Related]
6. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
7. Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2.
Scott MG; Le Rouzic E; Périanin A; Pierotti V; Enslen H; Benichou S; Marullo S; Benmerah A
J Biol Chem; 2002 Oct; 277(40):37693-701. PubMed ID: 12167659
[TBL] [Abstract][Full Text] [Related]
8. Endothelin-converting enzyme 1 and β-arrestins exert spatiotemporal control of substance P-induced inflammatory signals.
Jensen DD; Halls ML; Murphy JE; Canals M; Cattaruzza F; Poole DP; Lieu T; Koon HW; Pothoulakis C; Bunnett NW
J Biol Chem; 2014 Jul; 289(29):20283-94. PubMed ID: 24898255
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
10. Chebulinic acid inhibits MDA-MB-231 breast cancer metastasis and promotes cell death through down regulation of SOD1 and induction of autophagy.
Sharma A; Mishra T; Thacker G; Mishra M; Narender T; Trivedi AK
Cell Biol Int; 2020 Dec; 44(12):2553-2569. PubMed ID: 32902904
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
Messeha SS; Zarmouh NO; Asiri A; Soliman KFA
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339
[TBL] [Abstract][Full Text] [Related]
12. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
13. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
14. Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer.
Lundgren K; Tobin NP; Lehn S; Stål O; Rydén L; Jirström K; Landberg G
J Mol Diagn; 2011 May; 13(3):340-51. PubMed ID: 21497294
[TBL] [Abstract][Full Text] [Related]
15. Cancer‑associated fibroblast‑derived LRRC15 promotes the migration and invasion of triple‑negative breast cancer cells via Wnt/β‑catenin signalling pathway regulation.
Yang Y; Wu H; Fan S; Bi Y; Hao M; Shang J
Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34726255
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer.
Wang H; Wu D; Cai L; Li X; Zhang Z; Chen S
J Cell Mol Med; 2020 Jun; 24(12):6869-6882. PubMed ID: 32394588
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
19. Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.
Shanle EK; Zhao Z; Hawse J; Wisinski K; Keles S; Yuan M; Xu W
Mol Endocrinol; 2013 Oct; 27(10):1762-75. PubMed ID: 23979844
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer.
Troschel FM; Minte A; Ismail YM; Kamal A; Abdullah MS; Ahmed SH; Deffner M; Kemper B; Kiesel L; Eich HT; Ibrahim SA; Götte M; Greve B
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
